Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jul:42:102201.
doi: 10.1016/j.msard.2020.102201. Epub 2020 May 15.

Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab

Kulachanya Suwanwongse  1 , Nehad Shabarek  2
Affiliations
Comment

Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab

Kulachanya Suwanwongse et al. Mult Scler Relat Disord. 2020 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest There was no conflicts of interest

Comment on

References

    1. Giovannoni G., Hawkes C., Lechner-Scott J., Levy M., Waubant E., Gold J. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult. Scler. Relat. Disord. 2020 - PMC - PubMed
    1. Kappos L., Racke M.K., Rammohan K., Traboulsee A., Hauser S.L., Julian L., Köndgen H., Li C., Napieralski J., Zheng H., Wolinsky J.S. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized opera I, opera II, and oratorio studies. Mult. Scler. Relat. Disord. 2019;30:236–243. - PubMed
    1. Novi G., Mikulska M., Briano F., Toscanini F., Tazza F., Uccelli A. COVID-19 in a MS patient treated with Ocrelizumab: does immunosuppression have a protective role? Mult. Scler. Relat. Disord. 2020 - PMC - PubMed

Substances